VEGF-Inhibitor Looks Promising for Malignant Mesothelioma
There is more encouraging news about the monoclonal antibody bevacizumab (Avastin) and its potential to boost the effectiveness of chemotherapy for people with malignant pleural mesothelioma. A pair of oncology researchers from Texas have just released their summary of the the most recent published studies on bevacizumab. They conclude that, for the right patients, bevacizumab may improve mesothelioma outcomes and extend survival by blocking tumor blood vessel formation (angiogenesis). This ability of bevacizumab to help standard mesothelioma chemotherapy work better is why the drug has been included as a possible first-line mesothelioma treatment in the National Comprehensive Cancer Network guidelines since 2016. Bevacizumab for Mesothelioma Therapy Bevacizumab is a monoclonal antibody that inhibits angiogenesis in mesothelioma tumors by blocking VEGF, a protein…